Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 237

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 237
---
-enriched microRNAs in plasma. Short-term objectives of DiamiR include the development of Lab-Developed tests
(LDTs) under CLIA guidelines based on the identified miRNA expression signatures. The tests will be used for screening, patient stratification,
as well as disease and treatment monitoring.

DiamiR was incorporated in Delaware on June 16,
2014, and primarily operates through its wholly-owned subsidiary, DiamiR, LLC, which was incorporated as a limited liability company in
Delaware on September 17, 2009. In October 2014, DiamiR entered into a Share Exchange Agreement with DiamiR, LLC, pursuant to which DiamiR
acquired 100% of the issued and outstanding units of DiamiR, LLC in exchange for 4,282,000 shares (100%) of DiamiR’s common stock
(the “Share Exchange”), and DiamiR, LLC became a wholly-owned subsidiary of DiamiR. The Share Exchange was recognized as a
combination of entities under common control as both DiamiR, LLC and DiamiR have been controlled before and after the transaction by the
same shareholders.

DiamiR has incurred net losses in each year since its inception, including
net losses of $614,405 and $1,318,431 for the years ended May 31, 2024 and 2023, respectively, and $493,710 for the nine months ended
February 28, 2025. At February 28, 2025, DiamiR had an accumulated deficit of $5,573,046, primarily due to operating expenses. DiamiR
has devoted most of its financial resources to conducting studies on analysis of circulating organ-enriched miRNA biomarkers and building
its patent portfolio. DiamiR has not completed development of any product candidate and has therefore not generated any revenues from
product sales. Because of the numerous risks and uncertainties associated with the development of DiamiR’s LDTs, DiamiR is unable
to accurately predict the timing or amount of increased expenses or when, or if, DiamiR will be able to achieve or maintain profitability.
DiamiR expects to incur increased expenses as it conducts its clinical studies. DiamiR also expects an increase in its expenses associated
with creating additional infrastructure (including hiring additional personnel) to develop and launch CogniMIR and support
operations. As a result, DiamiR expects to continue to incur net